A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain

计划入组 35 人 · 首次发布于 2026 年 5 月 20 日

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)

计划入组 2 人 · 首次发布于 2021 年 12 月 17 日

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

计划入组 98 人 · 首次发布于 2021 年 3 月 26 日

Bifunctional complement inhibitor

complement C3 analog

HC3-1496

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

Immuno Cure 3 Limited

Novartis Reports Positive Phase III Results for Fabhalta in Rare Kidney Disease C3 Glomerulopathy

Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy

FDA Grants Rare Pediatric Disease Designation to Omeros' Zaltenibart for C3 Glomerulopathy